Medicines from Waste: Pioneering the Path from Plastics to Paracetamol Review

Made from a variety of organic compounds, including ethylene, vinyl chloride, vinyl acetate, vinyl alcohol, and others, plastic is a synthetic polymeric material with a high molecular weight. Petroleum, coal, and natural gas are the primary raw materials used to make plastics. The materials used to make plastics have a variety of drawbacks despite their many positive effects on human society. Di-(2-ethylhexyl) phthalate (DEHP), bisphenol A (BPA), polyhalogenated compounds, and heavy metals are just a few of the harmful additives found in plastics that may be harmful to human health (Boyu Jiang, 2020). In addition to the pharmaceutical industry's continued heavy reliance on fossil fuels for the production of active
pharmaceutical ingredients, plastic waste presents a serious environmental threat. According to the researchers, who are from AstraZeneca and the University of Edinburgh in the United Kingdom, their work shows an integrated chemical and biological approach for upcycling and sustainable plastic remediation (Robinson, 2025). The recent discovery uses Escherichia coli to produce paracetamol in less than 24 hours, addressing the pressing need to recycle
polyethylene terephthalate (PET), a common plastic that eventually ends up in landfills or pollutes oceans. (ed.ac.uk, 2025) (wired, 2025). On an industrial scale, the yields are modest, but each one-litre soft drink bottle would yield about nine standard 500 mg tablets (ralls,
2025). This review highlights the sustainability potential of this process, discusses its implications for circular economy strategies in pharmaceutical manufacturing, and summarises the new biotechnological and synthetic advancements that underlie it.